<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612283</url>
  </required_header>
  <id_info>
    <org_study_id>NUTRIN004</org_study_id>
    <nct_id>NCT04612283</nct_id>
  </id_info>
  <brief_title>NGA-01 Gel for the Treatment of Osteoarthritis With Joint Pain</brief_title>
  <official_title>A Double Blind, Randomized, Parallel Group Study to Evaluate Efficacy and Safety of NGA-01 Gel Against Placebo in the Treatment of Osteoarthritis With Joint Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutrin GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galaxa Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mittal Global Clinical Trial Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nutrin GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis is characterized by the breakdown of cartilage in joints. As cartilage&#xD;
      deteriorates, the bones of the joint begin to run against one another, causing stiffness and&#xD;
      pain, which often impairs movement. Osteoarthritis also can damage ligaments, menisci, and&#xD;
      muscles. Bone or cartilage fragments may float in the joint space, causing irritation and&#xD;
      pain. Bone spurs, or osteophytes, may also develop, causing additional pain and potentially&#xD;
      damaging surrounding tissues. Around the world, an estimated 10%-15% of adults over 60 have&#xD;
      some degree of osteoarthritis. It most commonly affects the joints in the knee, hands, feet,&#xD;
      and spine, and is also relatively common in other joints such as the shoulder and hip joints.&#xD;
      There are two types of osteoarthritis: primary and secondary. Primary osteoarthritis is a&#xD;
      chronic degenerative disease that is related to, but not caused by, aging. As a person ages,&#xD;
      the water content of their cartilage decreases, thus weakening it and making it less&#xD;
      resilient and more susceptible to degradation. There are strong indications that genetic&#xD;
      inheritance is a factor, as up to 60% of all OA cases are thought to result from genetic&#xD;
      factors. The main symptoms are pain, loss of ability, and &quot;joint stiffness after exercise or&#xD;
      use.&quot; These symptoms are often aggravated by activity or rigorous exercise and relieved&#xD;
      during rest, though the disease may eventually progress to the point where the patient even&#xD;
      feels pain when resting, and some people report pain so intense that it wakes them up when&#xD;
      they are sleeping. Osteoarthritis, at present, cannot be cured, and will likely get worse&#xD;
      over time, but the symptoms can be controlled. Treatments vary widely, from alternative&#xD;
      medicine, to lifestyle changes such as exercise and diet, to physical aids such as canes or&#xD;
      braces, to medications such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS),&#xD;
      corticosteroids, and more. Osteoarthritis is the most common joint disease of human. Among&#xD;
      the elderly knee osteoarthritis is leading cause of chronic disability in developed&#xD;
      countries. Some people in India are unable to walk independently from bed and bath-room&#xD;
      because of Osteoarthritis of the knee or hip joint. Osteoarthritis (OA) also known as&#xD;
      degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities&#xD;
      involving degradation of joints, including articular cartilage and subchondral bone. Symptoms&#xD;
      may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. A variety&#xD;
      of causes viz. hereditary, developmental, metabolic, and mechanical may initiate processes&#xD;
      leading to loss of cartilage. When bone surfaces are not well protected by cartilage, bone&#xD;
      may get exposed and damaged. As a result of decreased movement secondary to pain, atrophy of&#xD;
      regional muscles, and ligaments may become more lax.&#xD;
&#xD;
      The goal of treatment is to reduce or eliminate the signs and symptoms of Osteoarthritis.&#xD;
      Mild to moderate disease is often treated with topical therapies. Sponsor has developed the&#xD;
      NGA-01Gel containing the fixed dose combination of alcohol and water mixture, with active&#xD;
      herbal ingredients, without preservatives and dyes. The Gel is easy to apply, and the&#xD;
      cosmetic appearance is that of a white, milky gel, easily-spreadable that absorbs completely&#xD;
      into the skin a few minutes after application and it is expected that the Gel will&#xD;
      differentiate from marketed formulations by patient preference for the gel and gel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind, randomized, parallel group study against placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain visual analog scale (VAS) scores (0-10) from baseline</measure>
    <time_frame>Day 0 - Day 60</time_frame>
    <description>Pain was recorded as per physician's analysis as per SOP, 0 as lowest and 10 as highest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC scores</measure>
    <time_frame>Day 0 - Day 60</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index is used to determine severity of arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Numeric Pain Rating Scale (NPRS) score</measure>
    <time_frame>Day 0 - Day 60</time_frame>
    <description>Pain is measured as per regular NPRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Range of motion (ROM)</measure>
    <time_frame>Day 0 - Day 60</time_frame>
    <description>physical assessment by the doctor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician's Global Assessment of Arthritis</measure>
    <time_frame>Day 0 - Day 60</time_frame>
    <description>The physicians analysed data is recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Assessment of Arthritis</measure>
    <time_frame>Day 0 - Day 60</time_frame>
    <description>The customer questionnaire based data is recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Arthritis Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>NGA-01 gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A formulation with natural ingredients expected to be used for joint pain in Osteoarthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel with no active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NGA-01 gel</intervention_name>
    <description>NGA-01 is a gel formulation with mostly herbal active ingredients</description>
    <arm_group_label>NGA-01 gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A Placebo with no active ingredients</description>
    <arm_group_label>Placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects having at least one or more sign and symptoms of Osteoarthritis like Pain in&#xD;
             joints (at Knee, Hip, Ankle, Elbow and Shoulder), stiffness, difficulty in flexion and&#xD;
             extension, crepitus, swelling etc for more than 3 months prior to the study.&#xD;
&#xD;
          -  Pain score of at least 4 cm on a 10-cm linear visual analogue scale.&#xD;
&#xD;
          -  Are free of any systemic or dermatologic disorder, which, in the opinion of the&#xD;
             investigator, will interfere with the study results or increase the risk of adverse&#xD;
             events.&#xD;
&#xD;
          -  Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation&#xD;
             (natural or artificial) for the duration of the study.&#xD;
&#xD;
          -  Are willing to refrain from using any lotions, gel, balm, moisturizer, cleansers,&#xD;
             cosmetics or creams, other than those issued as part of the study, on the treatment&#xD;
             areas during the treatment period.&#xD;
&#xD;
          -  If female of childbearing potential, must be willing to practice an acceptable form of&#xD;
             birth control for the duration of the study.&#xD;
&#xD;
          -  Are able to give written informed consent in a manner approved by the Institutional&#xD;
             Ethics Committee and comply with the requirements of the study.&#xD;
&#xD;
          -  Are willing to avoid participation in any other interventional clinical trial for the&#xD;
             duration of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant, breast-feeding, or planning to become pregnant during the study.&#xD;
&#xD;
          -  Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis,&#xD;
             Gouty Arthritis.&#xD;
&#xD;
          -  Complications of OA, like Pseudogout, Spontaneous osteonecrosis of the knee, Ruptured&#xD;
             Baker cyst, Bursitis, Anserine bursitis (knee)interfere with the disease and&#xD;
             treatment.&#xD;
&#xD;
          -  Severe Stomach infection.&#xD;
&#xD;
          -  Severely traumatised and/or very severe or mucosal inflammation&#xD;
&#xD;
          -  Peritonsillar abscess&#xD;
&#xD;
          -  Long term use (â‰¥ 3 times per week within the last month or regular intake within the&#xD;
             last 3 months before randomisation) of antiinflammatory drugs- Any long-acting or slow&#xD;
             release analgesic intake including Non Steroidal Anti-Inflammatory Drugs&#xD;
             (NSAIDs)within 24 hours before randomisation (e.g. piroxicam or naproxen)&#xD;
&#xD;
          -  Any anti-inflammatory drugs intake by systemic route within 12 hours before&#xD;
             randomization&#xD;
&#xD;
          -  Any paracetamol intake within 6 hours before randomisation&#xD;
&#xD;
          -  Any cold medication (decongestant, antihistamine, expectorant, antitussive) within 6&#xD;
             hours before randomisation&#xD;
&#xD;
          -  Heavy smokers (&gt;10 cigarettes/day)&#xD;
&#xD;
          -  Have open sores or open lesions in the treatment area(s).&#xD;
&#xD;
          -  Have any condition that, in the opinion of the investigator, would confound the safety&#xD;
             and/or efficacy assessments of plaque Arthritis.&#xD;
&#xD;
          -  Have participated in any interventional clinical trial in the previous 30 days.&#xD;
&#xD;
          -  Have a known sensitivity to any of the constituents of the test product&#xD;
&#xD;
          -  Have used, are using, or are planning to use immunosuppressive or immunomodulatory&#xD;
             medication (i.e., biologics), including oral or parenteral corticosteroids.&#xD;
&#xD;
          -  Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or&#xD;
             illegal drug/substance abuse in the past 2 years.&#xD;
&#xD;
          -  Plan to seek alternative treatment of any kind for their Arthritis, in the eligible&#xD;
             treatment areas or otherwise, during the trial period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rosemarie Dauer</last_name>
    <phone>+4995434437508</phone>
    <email>research@nutrin.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Puneet Mittal</last_name>
    <phone>+15105005624</phone>
    <email>puneetmittal@mgcts.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moraya Multispeciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mukund Dr Diggikar</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This is a blinded gel trial with efficacy and safety data to be evaluated. Being a confidential formulation, we are not very sure and have no plans to share any data till date.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

